Victor Tieu

CRISPR for better cell therapies
@Stanford PhD 🌲 · @UCBerkeley 🐻

Stanley Qi & Crystal Mackall labs

[Victor Tieu @victortieu]

🗣️wahoo!!! my doctoral work is out online in @CellCellPress: https://t.co/OBbpudQRvq!! couldn't have done it without my two wonderful labs and co-advisors @stanleyqilab & @MackallLab

we developed a new RNA-targeting CRISPR platform (MEGA) to engineer better T cell therapies...🧵

[Victor Tieu @victortieu]

*in british accent* reprogramme ☕ T cell phenotype and function

[Victor Tieu @victortieu]

so grateful for the opportunity to highlight our work on multiplexed transcriptome engineering & combinatorial screening for better CAR T cell therapies in the latest issue of @NatureRevCancer!!
📄: https://t.co/hVsAsKzAMI

[National Human Genome Research Institute @genome_gov]

We’re still in our BRAT summer by sharing our new RNA resources! Improved understanding of RNA over the years has led to huge developments, such as creating a COVID vaccine that saved millions of lives. Learn more in our new fact sheet! https://t.co/f0bpvxV1ov

[Victor Tieu @victortieu]

@KipnissNathan THE ANGST

[Victor Tieu @victortieu]

yes!! i've long suspected that this was the case since essentially all prior cas13d collateral cleavage studies were done in transfected cell lines. it's so great to see this important & rigorous study out – congrats to the team!!

[Neville Sanjana @nevillesanjana]

🚨New lab preprint! 🚨

A deep dive to shed light on a long-standing controversy with RNA-targeting CRISPRs: Do they have high levels of collateral (trans) cleavage of other RNAs in the cell ✂️✂️✂️ — or not?

New work from talented PhD student #SydneyHart & others in our lab. 📰

[Nature Biotechnology @NatureBiotech]

Engineered CRISPR-Cas12a for higher-order combinatorial chromatin perturbations https://t.co/eXKmBFK5ic

[Victor Tieu @victortieu]

when in new york

[Nature Biotechnology @NatureBiotech]

Bidirectional epigenetic editing reveals hierarchies in gene regulation https://t.co/IziHMe3bsx

[nature @Nature]

Nature research paper: Engineered CD47 protects T cells for enhanced antitumour immunity https://t.co/DIYmwmkupi

[Victor Tieu @victortieu]

thanks @GenomeSeminars @harvardmed for inviting me to give a talk on MEGA recently!! really great opportunity for young scientists/first authors to present & discuss their work. seminars are weekly, totally free to attend (zoom), and recorded/posted here: https://t.co/EHNlUWRQJz

[Victor Tieu @victortieu]

!!!!!

[Evan Weber @EvanWeberPhD]

In summary, memory programming (but not TOO much memory) is a great thing for CAR T! FOXO1 is critical for mediating CAR T function and FOXO1 overexpression represents a broadly-applicable approach to enhance CAR T antitumor activity. The jury is still out on TCF1/TCF7. 13/

[Parker Institute for Cancer Immunotherapy @parkerici]

Check out the latest findings from PICI Center Director at @StanfordMed Crystal Mackall, MD, @MackallLab. The PICI-funded research suggests cell therapies for #cancer could see improvements with use of a new CRISPR RNA-editing platform called MEGA. Learn more in @CellCellPress

[Victor Tieu @victortieu]

wow!! thank you @ACIR_org & lauren hitchings for the wonderful writeup and visual summary of our work!!

[ACIR @ACIR_org]

MEGA is a CRISPR-Cas13d system that allows for knockdown of gene expression at the genetic level, offering several unique advantages over CRISPR-Cas9 👉 https://t.co/MHHo6wAVTs @StanfordMed

[Sarafan ChEM-H @Stanford_ChEMH]

Lead author Victor Tieu, @stanleyqilab, Crystal Mackall @MackallLab & team discovered a way to potentially improve CAR T therapies using a CRISPR RNA-editing platform—Multiplexed Effector Guide Arrays (MEGA)—that boosts the cells’ ability to target tumors https://t.co/PUP4Mld2gs

[Victor Tieu @victortieu]

@DravenRane @CellCellPress @stanleyqilab @MackallLab thanks draven!!!!! 🥹✨

[Victor Tieu @victortieu]

🗣️wahoo!!! my doctoral work is out online in @CellCellPress: https://t.co/OBbpudQRvq!! couldn't have done it without my two wonderful labs and co-advisors @stanleyqilab & @MackallLab

we developed a new RNA-targeting CRISPR platform (MEGA) to engineer better T cell therapies...🧵

[Nature Biotechnology @NatureBiotech]

A CRISPR-Cas13d based platform MEGA enables safer, more controllable editing of T cells to enhance CAR T therapy via reversible, multiplexed gene knockdown without cutting genomic DNA. #NBThighlight
https://t.co/DQ75g9Ygb4

[Stanford Cancer Institute @StanfordCancer]

SCI members Stanley Qi, Crystal Mackall & team pioneered MEGA, a #CRISPR RNA-editing tool enhancing #CARTcells precision against tumors. https://t.co/T7iW3wZOuY @stanleyqilab @MackallLab

[Victor Tieu @victortieu]

@pdhsu senpai noticed me 👀

[Victor Tieu @victortieu]

big thanks to @Nature for featuring our work!!

[nature @Nature]

A CRISPR-based system that edits RNA rather than DNA can give new life to exhausted CAR T cells https://t.co/mJFK1fKJM7